Production (Stage)
Lotus Bio-Technology Development Corp.
LBTD
$0.00
$0.000.00%
OTC PK
| 12/31/2017 | 09/30/2017 | 06/30/2017 | 03/31/2017 | 12/31/2016 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -98.02% | -95.75% | -97.32% | -97.14% | 5,861.31% |
| Depreciation & Amortization | -245.45% | -245.45% | -245.45% | -245.45% | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -98.23% | -95.96% | -97.53% | -97.35% | 5,869.34% |
| Operating Income | 98.23% | 95.96% | 97.53% | 97.35% | -5,869.34% |
| Income Before Tax | 98.37% | 96.11% | 97.68% | 97.50% | -6,231.78% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 98.37% | 96.11% | 97.68% | 97.50% | -6,231.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 98.37% | 96.11% | 97.68% | 97.50% | -6,231.78% |
| EBIT | 98.23% | 95.96% | 97.53% | 97.35% | -5,869.34% |
| EBITDA | -- | 98.46% | 98.46% | 98.40% | -- |
| EPS Basic | 97.73% | 92.86% | 95.24% | 95.24% | -4,500.00% |
| Normalized Basic EPS | 96.30% | 92.31% | 96.15% | 96.15% | -2,800.00% |
| EPS Diluted | 97.73% | 92.86% | 95.24% | 95.24% | -4,500.00% |
| Normalized Diluted EPS | 96.30% | 92.31% | 96.15% | 96.15% | -2,800.00% |
| Average Basic Shares Outstanding | 46.69% | -28.18% | -47.24% | -54.40% | -40.61% |
| Average Diluted Shares Outstanding | 46.69% | -28.18% | -47.24% | -54.40% | -40.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |